Several markers, such as the transcriptional effector RPL22, a candidate gene involved in nodal/transforming growth factor-β and the ribosomal protein–murine double minute 2 (MDM2)–p53 signaling pathway [4], as well as different methylation rates of CACNA1G, NEUROG1, and CDKN2A (p16) [1], might confound analyses of the prognosis of synchronous CRC. The gene discussed is RPL22; the disease is colorectal carcinoma.